{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:38Z","timestamp":1781647058757,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["23K08035"],"award-info":[{"award-number":["23K08035"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The 21-gene Oncotype DX Recurrence Score (RS) is widely used to guide adjuvant chemotherapy decisions in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, the clinical interpretation of RS remains challenging in premenopausal women with node-positive disease, where discordance between genomic and clinicopathological risk is frequently encountered. This study aimed to elucidate the determinants of clinical\u2013genomic risk discordance and to clarify its impact on real-world treatment selection, with a specific focus on premenopausal node-positive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 290 patients with HR+\/HER2- breast cancer who underwent curative surgery and Oncotype DX testing between September 2023 and November 2025. Clinical risk was defined according to the St. Gallen criteria, and concordance or discordance was determined based on agreement or disagreement between clinical risk and RS. Logistic regression analyses were performed to identify predictors of discordance in the overall cohort and in node-positive patients. Treatment allocation was further examined in a predefined subgroup of 28 premenopausal patients with node-positive disease. Treatment strategies were categorized as chemotherapy plus endocrine therapy, endocrine therapy combined with systemic intensification (abemaciclib or S-1), or endocrine therapy alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinical\u2013genomic risk discordance was observed in 123 patients (42.4%). In multivariable analysis of the overall cohort, larger tumor size (OR 8.33) and nodal positivity (OR 6.43) were independently associated with discordance, indicating a strong association with tumor burden. In contrast, among node-positive patients, premenopausal status (OR 0.18,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045) and high proliferative activity (Ki-67\u2009&gt;\u200920%; OR 4.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048) were independently associated with discordance, indicating a distinct biological pattern associated with proliferative activity in premenopausal disease. In the premenopausal node-positive subgroup, all concordant cases received intravenous chemotherapy, whereas discordant cases showed marked heterogeneity in treatment selection: chemotherapy in 2 patients (8.0%), endocrine therapy combined with targeted or fluoropyrimidine-based intensification strategies (including abemaciclib or S-1) in 11 patients (44.0%), and endocrine therapy alone in 12 patients (\n                      <jats:italic>p &lt;<\/jats:italic>\n                      0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical\u2013genomic risk discordance is frequent in premenopausal women with node-positive hormone receptor-positive, HER2-negative breast cancer and is associated with distinct biological characteristics, including high proliferative activity. In real-world clinical practice, discordance was linked to substantial variation in adjuvant treatment selection, with many patients managed using endocrine-based strategies. These findings highlight the clinical relevance of integrating genomic and clinicopathological information in treatment decision-making and support the role of genomic assays as complementary tools for individualized therapy in this challenging population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15913-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:48:29Z","timestamp":1775472509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical\u2013genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Mariko","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Kochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Ogisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhito","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsune","family":"Shibutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Morisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"27","key":"15913_CR1","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"15913_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"25","key":"15913_CR3","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"10","key":"15913_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B, Weber WP, Poortmans P, Regan MM, et al. Customizing local and systemic therapies for women with early breast cancer: St. Gallen Consensus 2021. Ann Oncol. 2021;32(10):1216\u201335.","journal-title":"Ann Oncol"},{"key":"15913_CR5","first-page":"213","volume":"13","author":"A Lombardi","year":"2021","unstructured":"Lombardi A, Lazzeroni R, Bersigotti L, Vitale V, Amanti C. The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up. Breast Cancer (Dove Med Press). 2021;13:213\u20137.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"2","key":"15913_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-3817-9","volume":"157","author":"S Bustreo","year":"2016","unstructured":"Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363\u201371.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"15913_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55\u201365.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15913_CR8","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28(11):1829\u201334.","journal-title":"J Clin Oncol"},{"key":"15913_CR9","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1038\/npjbcancer.2016.17","volume":"2","author":"VI Petkov","year":"2016","unstructured":"Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer. 2016;2:16017.","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"15913_CR10","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med"},{"issue":"10","key":"15913_CR11","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1200\/JCO.18.00028","volume":"37","author":"U Nitz","year":"2019","unstructured":"Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al. West German study planB trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol. 2019;37(10):799\u2013808.","journal-title":"J Clin Oncol"},{"issue":"23","key":"15913_CR12","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2017.72.3494","volume":"35","author":"B Ejlertsen","year":"2017","unstructured":"Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, H\u00f8jris I, et al. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol. 2017;35(23):2639\u201346.","journal-title":"J Clin Oncol"},{"issue":"3","key":"15913_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.annonc.2021.12.004","volume":"33","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, et al. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022;33(3):234\u20138.","journal-title":"Ann Oncol"},{"issue":"3","key":"15913_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","volume":"6","author":"JA Sparano","year":"2020","unstructured":"Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, et al. Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial. JAMA Oncol. 2020;6(3):367\u201374.","journal-title":"JAMA Oncol"},{"issue":"2","key":"15913_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1200\/JCO.20.00853","volume":"39","author":"R Buus","year":"2021","unstructured":"Buus R, Sestak I, Kronenwett R, Ferree S, Schnabel CA, Baehner FL, et al. Molecular drivers of oncotype DX, prosigna, endopredict, and the breast cancer index: a TransATAC study. J Clin Oncol. 2021;39(2):126\u201335.","journal-title":"J Clin Oncol"},{"issue":"6","key":"15913_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.20.03007","volume":"39","author":"JA Sparano","year":"2021","unstructured":"Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021;39(6):557\u201364.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15913_CR17","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/cncr.35163","volume":"130","author":"AGL Vannier","year":"2024","unstructured":"Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, et al. Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024;130(8):1210\u201320.","journal-title":"Cancer"},{"issue":"34","key":"15913_CR18","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15913_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(20)30534-9","volume":"22","author":"M Toi","year":"2021","unstructured":"Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, et al. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(1):74\u201384.","journal-title":"Lancet Oncol"},{"issue":"12","key":"15913_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Fasching PA, Patel R, Verma S, Hurvitz SA, Chia S, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391.","journal-title":"N Engl J Med"},{"issue":"3","key":"15913_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA. 2024;331(3):233\u201341.","journal-title":"JAMA"},{"issue":"16","key":"15913_CR22","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC Jr, Barlow W, et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022;40(16):1816\u201337.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15913_CR23","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220.","journal-title":"Ann Oncol"},{"issue":"5","key":"15913_CR24","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.18.01160","volume":"37","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423\u201338.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15913_CR25","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10549-020-06075-6","volume":"186","author":"P Qi","year":"2021","unstructured":"Qi P, Yang Y, Bai Q-M, Xue T, Ren M, Yao Q-L, et al. Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients. Breast Cancer Res Treat. 2021;186(2):327\u201342.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"15913_CR26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1055\/a-1111-8734","volume":"80","author":"P Vincent","year":"2020","unstructured":"Vincent P, W\u00f6ckel A, Kreienberg R, Wischnewsky M, Blettner M. Distribution of the 21-gene breast recurrence score in patients with primary breast cancer in Germany. Geburtshilfe Frauenheilkd. 2020;80(6):619\u201327.","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"4","key":"15913_CR27","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1245\/s10434-023-14835-z","volume":"31","author":"T Higgins","year":"2024","unstructured":"Higgins T, Kantor O, Harrison B, Giordano J, McGrath M, Burstein HJ, et al. Defining the biology of estrogen receptor-low-positive breast cancer. Ann Surg Oncol. 2024;31(4):2244\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"10384","key":"15913_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(23)00285-4","volume":"401","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2023","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023;401(10384):1277\u201392.","journal-title":"Lancet"},{"issue":"7","key":"15913_CR29","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1634\/theoncologist.2017-0346","volume":"23","author":"S Torres","year":"2018","unstructured":"Torres S, Trudeau M, Gandhi S, et al. Prospective evaluation of the impact of the 21-gene recurrence score assay on adjuvant treatment decisions for women with node-positive hormone receptor\u2013positive breast cancer in Ontario, Canada. Oncologist. 2018;23(7):768\u201375.","journal-title":"Oncologist"},{"key":"15913_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41523-017-0034-6","volume":"3","author":"SM Stemmer","year":"2017","unstructured":"Stemmer SM, Steiner M, Rizel S, Soussan-Gutman L, Bareket-Samish A, Ben-Baruch N, et al. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer. 2017;3:33.","journal-title":"NPJ Breast Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15913-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15913-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15913-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:32:06Z","timestamp":1781645526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15913-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15913"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15913-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Osaka Metropolitan University (approval number: #2025-045). The requirement for written informed consent was waived owing to the retrospective nature of the study and the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"617"}}